Sodium hyaluronate has been discovered for nearly 80 years. As early as 1934, Meyer and Palmer separated a macromolecular polysaccharide containing uronic acid and hexosamine from bovine vitreous, and named it "hyaluronic acid". The word "glassy" is a combination of "transparent, glassy" and "uronic acid". Biochemical terms are translated into "hyaluronic acid", which is called "hyaluronic acid" in China Pharmacopoeia and national drug standards. Hyaluronic acid is a polyanion in a physiologically neutral environment. In 1985, Balazs et al. suggested using the word hyaluronic acid to name the substance, on the grounds that the substance is essentially a carbohydrate and should be named according to the naming rules of glycosaminoglycans, that is, it should be represented by the suffix an. "Hyaluronic acid" has been widely used, covering hyaluronic acid and its salts in any state. Usually translated as "hyaluronic acid", abbreviated as HA. At present, HA products with drug standard names are usually called "sodium hyaluronate injection", and HA products with mechanical standard names are called medical sodium hyaluronate gel. As early as the late 1970s, the United States first developed the first product of this substance, which can be used in human clinic. Because this product is used in ophthalmic microsurgery-cataract surgery, its main function is to temporarily support the operating space for clinicians as the operating pad for ophthalmic microsurgery, which is convenient for the smooth implementation of the operation, so it is approved to be listed with the instrument. Subsequently, this product came out one after another in orthopedics and surgery, and all of them were listed under the instrument number. Therefore, the FDA of the United States recognized the substance as a medical device.